Jim Wassil Sells 3,477 Shares of Vaxcyte (NASDAQ:PCVX) Stock

Key Points

• Vaxcyte COO Jim Wassil sold 3,477 shares at an average price of $61.07, generating $212,340.39. The sale covered tax-withholding obligations, leaving him with 155,041 shares worth approximately $9.47 million.
• Vaxcyte shares rose 1.3% to $61.58, while the company reported quarterly EPS of negative $1.97, beating analysts’ expectations of negative $2.06. Institutional investors own approximately 96.78% of the stock.
• Analyst sentiment remains a consensus “Moderate Buy”, with five Buy, two Hold and one Sell rating; the average price target is $86, well above the current share price.

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 3,477 shares of the company's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $61.07, for a total transaction of $212,340.39. Following the sale, the chief operating officer directly owned 155,041 shares in the company, valued at approximately $9,468,353.87. The trade was a 2.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Stock Up 1.3%

PCVX stock traded up $0.77 during trading on Wednesday, hitting $61.58. The company had a trading volume of 1,021,280 shares, compared to its average volume of 997,397. The firm has a 50-day moving average price of $57.98 and a 200-day moving average price of $56.12. Vaxcyte, Inc. has a 1-year low of $30.81 and a 1-year high of $65.00. The firm has a market cap of $9.16 billion, a PE ratio of -8.07 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, beating analysts' consensus estimates of ($2.06) by $0.09. During the same period in the previous year, the company earned ($1.22) earnings per share. Sell-side analysts anticipate that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in shares of Vaxcyte by 156.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company's stock worth $27,000 after buying an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company's stock valued at $30,000 after buying an additional 600 shares during the period. EverSource Wealth Advisors LLC boosted its position in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company's stock worth $34,000 after acquiring an additional 184 shares during the last quarter. Capital Advisors Ltd. LLC purchased a new stake in Vaxcyte in the 1st quarter worth approximately $58,000. Finally, Allworth Financial LP acquired a new position in Vaxcyte in the 2nd quarter valued at $75,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PCVX has been the subject of several research reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vaxcyte in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Vaxcyte from a "strong sell" rating to a "sell" rating in a report on Saturday, August 8th. Finally, Zacks Research raised shares of Vaxcyte from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc NASDAQ: PCVX is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source